Azitra, Inc.
AMEX:AZTRBiotechnology
+$0.82 today
- Market cap
- $92.72M
- Beta
- -1.04
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$0.64
Volume 146.25M
Average 11.12M
AZTR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Azitra, Inc.AMEX: AZTR
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development dips below year-ago levels
Q2 FY2026 research & development of $1.35M fell 3.6% year over year, behind the +6.5% change in trailing-twelve-month research & development. Sequentially, it fell 13.4% from the prior quarter. Over 3 fiscal years it compounded at -7.4% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -3.6% toward the trailing-twelve-month pace of +6.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 4.84M USD
- Year-over-year change
- +2.4%
- 4-year CAGR
- -2.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.84M | +2.4% |
| FY2024 | 2024-12-31 | 4.72M | +29.6% |
| FY2023 | 2023-12-31 | 3.64M | -40.3% |
| FY2022 | 2022-12-31 | 6.1M | +13.3% |
| FY2021 | 2021-12-31 | 5.38M | — |
Research & Development vs competitors
How AZTR compares with its peers on the latest reported figures
- AZTR's LTM Jun 2026 research & development of $5.1M is the lowest of the 2 companies compared; the peer median is $7.02M.
- Its year-over-year change of +6.5% is the highest of 2, against a peer median of -17.1%.
- Over three fiscal years its annual growth of -7.4% compares with a peer median of +13.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.02M | -17.1% | +13.9% | — | |
| LTM Jun 2026 | $5.1M | +6.5% | -7.4% | — | |
| Peer median (excluding AZTR) | $7.02M | -17.1% | +13.9% | — | |
Competitors are the stored peer set for AZTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 110K | 284K | 686K | 7.5K | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 110K | 284K | 686K | 7.5K | 0 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Research & Development | 5.38M | 6.1M | 3.64M | 4.72M | 4.84M |
| Selling, General & Admin | 3.95M | 3.64M | 4.49M | 6.27M | 6.13M |
| Operating Expenses | 9.33M | 9.74M | 8.14M | 10.99M | 10.97M |
| Depreciation & Amortization | 84.77K | 405.98K | 425.55K | 448.24K | 453.14K |
| EBITDA | (8.79M) | (10.02M) | (10.67M) | (8.5M) | (10.49M) |
| EBITDA Margin | -7989.0% | -3529.0% | -1555.9% | -113307.5% | — |
| Operating Income | (9.22M) | (9.45M) | (7.45M) | (10.99M) | (10.97M) |
| Operating Margin | -8383.1% | -3328.7% | -1086.1% | -146468.5% | — |
| Interest Income | 8.76K | 4.82K | 1.58K | 122.55K | 70.21K |
| Interest Expense | 66.97K | 251.89K | 167.73K | 12.16K | 7.59K |
| Other Income / Expenses | 281.78K | (1.23M) | (3.82M) | 2.03M | 19.61K |
| Income Before Tax | (8.94M) | (10.68M) | (11.27M) | (8.96M) | (10.95M) |
| Pre-Tax Margin | -8127.0% | -3760.7% | -1642.3% | -119446.1% | — |
| Income Tax Expense | 0 | 0 | 17.31K | 9.03K | 8.32K |
| Net Income | (8.94M) | (10.68M) | (11.28M) | (8.97M) | (10.96M) |
| Net Margin | -8127.0% | -3760.7% | -1644.9% | -119566.6% | — |
| EPS (Basic) | (193.55) | (222.33) | (208.74) | (15.78) | (2.25) |
| EPS (Diluted) | (193.55) | (222.33) | (208.74) | (15.78) | (2.25) |
| Weighted Avg Shares | 60.49K | 60.49K | 60.55K | 568.24K | 4.87M |
| Weighted Avg Shares (Diluted) | 60.49K | 60.49K | 60.55K | 568.24K | 4.87M |
Azitra, Inc.
AMEX:AZTR
Intrinsic Alpha fair value
Locked
Current Price
$1.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.